- Home
- IRON vs ERAS Comparison
IRON vs ERAS Comparison
Compare IRON & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- ERAS
- Stock Information
- Founded
- IRON 2017
- ERAS 2018
- Country
- IRON United States
- ERAS United States
- Employees
- IRON N/A
- ERAS N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- ERAS Health Care
- Exchange
- IRON Nasdaq
- ERAS Nasdaq
- Market Cap
- IRON 1.9B
- ERAS 723.8M
- IPO Year
- IRON N/A
- ERAS 2021
- Fundamental
- Price
- IRON $57.83
- ERAS $1.93
- Analyst Decision
- IRON Strong Buy
- ERAS Strong Buy
- Analyst Count
- IRON 10
- ERAS 5
- Target Price
- IRON $73.70
- ERAS $5.70
- AVG Volume (30 Days)
- IRON 245.9K
- ERAS 1.3M
- Earning Date
- IRON 11-12-2024
- ERAS 11-12-2024
- Dividend Yield
- IRON N/A
- ERAS N/A
- EPS Growth
- IRON N/A
- ERAS N/A
- EPS
- IRON N/A
- ERAS N/A
- Revenue
- IRON N/A
- ERAS N/A
- Revenue This Year
- IRON N/A
- ERAS N/A
- Revenue Next Year
- IRON N/A
- ERAS N/A
- P/E Ratio
- IRON N/A
- ERAS N/A
- Revenue Growth
- IRON N/A
- ERAS N/A
- 52 Week Low
- IRON $25.60
- ERAS $1.64
- 52 Week High
- IRON $77.60
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- IRON 37.45
- ERAS 28.40
- Support Level
- IRON $57.09
- ERAS $2.65
- Resistance Level
- IRON $62.20
- ERAS $2.84
- Average True Range (ATR)
- IRON 2.88
- ERAS 0.18
- MACD
- IRON -0.82
- ERAS -0.05
- Stochastic Oscillator
- IRON 8.16
- ERAS 4.69
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.